M. Imani, Rowshanak Abbasi, F. Golgiri, A. Khajavi, Hamideh Akbari
Background: Hyperprolactinemia is associated with changes in body composition and metabolic abnormalities. Normalization of prolactin (PRL) has been suggested to reverse these abnormalities. The present study was designed to determine the effect of treatment duration on metabolism as well as metabolic alterations after treatment in comparison with baseline in patients with prolactinoma in Iranian individuals. Methods: In a prospective and longitudinal study, 27 consecutive patients with prolactinoma were assessed during 6 months. Anthropometric data and metabolic variables were studied at baseline and at 3 and 6 months after normalization of PRL. Results: In the present study, there was a statistically significant decrease of metabolic syndrome (Met.S) after 3 months (P = 0.01), with a further decline after 6 months (P < 0.001) of cabergoline therapy. Moreover, a statistically significant decline was seen in total cholesterol (P = 0.007 and P = 0.01 after 3 and 6 months, respectively) and uric acid (P = 0.05 and P = 0.03 after 3 and 6 months, respectively) after normalization of the serum PRL. Conclusions: We found a significant reduction in Met.S after normalization of PRL level in patients with prolactinoma. We suggest that it is important to consider the metabolic profile of patients with prolactinoma. Then, patients may benefit even at 3 months after treatment.
{"title":"The effect of treatment duration on metabolic parameters in patients with prolactinoma: A prospective longitudinal study","authors":"M. Imani, Rowshanak Abbasi, F. Golgiri, A. Khajavi, Hamideh Akbari","doi":"10.4103/jdep.jdep_2_19","DOIUrl":"https://doi.org/10.4103/jdep.jdep_2_19","url":null,"abstract":"Background: Hyperprolactinemia is associated with changes in body composition and metabolic abnormalities. Normalization of prolactin (PRL) has been suggested to reverse these abnormalities. The present study was designed to determine the effect of treatment duration on metabolism as well as metabolic alterations after treatment in comparison with baseline in patients with prolactinoma in Iranian individuals. Methods: In a prospective and longitudinal study, 27 consecutive patients with prolactinoma were assessed during 6 months. Anthropometric data and metabolic variables were studied at baseline and at 3 and 6 months after normalization of PRL. Results: In the present study, there was a statistically significant decrease of metabolic syndrome (Met.S) after 3 months (P = 0.01), with a further decline after 6 months (P < 0.001) of cabergoline therapy. Moreover, a statistically significant decline was seen in total cholesterol (P = 0.007 and P = 0.01 after 3 and 6 months, respectively) and uric acid (P = 0.05 and P = 0.03 after 3 and 6 months, respectively) after normalization of the serum PRL. Conclusions: We found a significant reduction in Met.S after normalization of PRL level in patients with prolactinoma. We suggest that it is important to consider the metabolic profile of patients with prolactinoma. Then, patients may benefit even at 3 months after treatment.","PeriodicalId":294186,"journal":{"name":"Journal of Diabetes and Endocrine Practice","volume":"21 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130304400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Heba, U. Parveen, Sara Khanum, Maaria Gulnaaz, Maimuna Tabassum, S. Safiyya
Until now, injectable glucagon was the only available treatment used in the management of severe hypoglycemia wherein glucagon had to be prepared in several steps before administration. This method of delivery of injectable glucagon being cumbersome and unappealing for wide majority of the patients had led to a search for an alternative route of drug delivery. nasal glucagon (NG) now serves an efficient, safe, easy-to-administer, and a favorable substitute to glucagon injections. This ready to use device stand in clear contrast to overcome the limitations associated with the currently available glucagon preparations has emerged a key advancement in the management of severe hypoglycemia in adolescents and children with type 1 diabetes. NG is now being developed and studied in other countries as well to meet the unmet need for an easy and convenient glucagon administration. This review covers the basic information of nasal glucagon, trials on nasal glucagon in children and adults and its potential uses, limitations, and future scope in practice.
{"title":"Nasal glucagon: A new hope for severe hypoglycemia in type 1 diabetes","authors":"S. Heba, U. Parveen, Sara Khanum, Maaria Gulnaaz, Maimuna Tabassum, S. Safiyya","doi":"10.4103/jdep.jdep_6_20","DOIUrl":"https://doi.org/10.4103/jdep.jdep_6_20","url":null,"abstract":"Until now, injectable glucagon was the only available treatment used in the management of severe hypoglycemia wherein glucagon had to be prepared in several steps before administration. This method of delivery of injectable glucagon being cumbersome and unappealing for wide majority of the patients had led to a search for an alternative route of drug delivery. nasal glucagon (NG) now serves an efficient, safe, easy-to-administer, and a favorable substitute to glucagon injections. This ready to use device stand in clear contrast to overcome the limitations associated with the currently available glucagon preparations has emerged a key advancement in the management of severe hypoglycemia in adolescents and children with type 1 diabetes. NG is now being developed and studied in other countries as well to meet the unmet need for an easy and convenient glucagon administration. This review covers the basic information of nasal glucagon, trials on nasal glucagon in children and adults and its potential uses, limitations, and future scope in practice.","PeriodicalId":294186,"journal":{"name":"Journal of Diabetes and Endocrine Practice","volume":"34 4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116492962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Admission hyperglycemia is known to cause increase in in-hospital mortality, increased length of intensive care unit (ICU) stay, increased morbidity across critically ill patients. In patients with vascular disease (myocardial infarction, stroke, etc.), this has been extensively studied. We planned to study the prevalence of admission hyperglycemia and its association with adverse outcomes in all critically ill patients. Methods: In an observational, prospective study, 200 critically ill inpatients admitted to the medicine ICU were included. The patients were stratified into known diabetes, newly detected diabetes, and stress hyperglycemia. Baseline clinical and laboratory parameters were collected, and Acute Physiology and Chronic Health Evaluation (APACHE)-II, Sequential Organ Failure Assessment (SOFA), and Simplified Acute Physiology (SAP II) scores were calculated. Data regarding clinical outcomes (discharge or in-hospital death) were also collected. Results: The prevalence of admission hyperglycemia and of stress hyperglycemia was found to be 11.99% and 1.51%, respectively. The newly detected diabetes had higher admission hyperglycemia and glycosylated hemoglobin. The prognostic scores – APACHE-II, SAP II, and SOFA scores – were worse among patients who died in the newly detected diabetes and the stress hyperglycemia group but not in the known diabetes group. The odds of death increased by 3.5 times with 1-day increase in the ICU. Conclusion: Our study concluded that the patients with newly detected diabetes and stress hyperglycemia had more severe illness as compared to the known diabetics.
背景:已知入院时高血糖会导致住院死亡率增加，重症监护病房(ICU)住院时间延长，危重患者发病率增加。在血管疾病(心肌梗死、中风等)患者中，这已被广泛研究。我们计划研究所有危重患者入院时高血糖的患病率及其与不良结局的关系。方法:采用观察性、前瞻性研究，对200例内科ICU危重住院患者进行分析。将患者分为已知糖尿病、新发现糖尿病和应激性高血糖。收集基线临床和实验室参数，计算急性生理和慢性健康评估(APACHE)-II、顺序器官衰竭评估(SOFA)和简化急性生理(SAP II)评分。还收集了有关临床结果(出院或院内死亡)的数据。结果:入院高血糖和应激性高血糖的患病率分别为11.99%和1.51%。新发现的糖尿病患者入院时高血糖和糖化血红蛋白较高。预后评分- APACHE-II, SAP -II和SOFA评分-在新发现的糖尿病和应激性高血糖组死亡的患者中更差，而在已知的糖尿病组中则没有。ICU时间每延长1天，死亡几率增加3.5倍。结论:我们的研究表明，与已知的糖尿病患者相比，新发现的糖尿病和应激性高血糖患者的病情更为严重。
{"title":"Admission hyperglycemia and adverse clinical outcomes in critically ill patients: A prospective, observational study","authors":"V. Jain, Sunil Bade, O. Gupta","doi":"10.4103/jdep.jdep_9_20","DOIUrl":"https://doi.org/10.4103/jdep.jdep_9_20","url":null,"abstract":"Background: Admission hyperglycemia is known to cause increase in in-hospital mortality, increased length of intensive care unit (ICU) stay, increased morbidity across critically ill patients. In patients with vascular disease (myocardial infarction, stroke, etc.), this has been extensively studied. We planned to study the prevalence of admission hyperglycemia and its association with adverse outcomes in all critically ill patients. Methods: In an observational, prospective study, 200 critically ill inpatients admitted to the medicine ICU were included. The patients were stratified into known diabetes, newly detected diabetes, and stress hyperglycemia. Baseline clinical and laboratory parameters were collected, and Acute Physiology and Chronic Health Evaluation (APACHE)-II, Sequential Organ Failure Assessment (SOFA), and Simplified Acute Physiology (SAP II) scores were calculated. Data regarding clinical outcomes (discharge or in-hospital death) were also collected. Results: The prevalence of admission hyperglycemia and of stress hyperglycemia was found to be 11.99% and 1.51%, respectively. The newly detected diabetes had higher admission hyperglycemia and glycosylated hemoglobin. The prognostic scores – APACHE-II, SAP II, and SOFA scores – were worse among patients who died in the newly detected diabetes and the stress hyperglycemia group but not in the known diabetes group. The odds of death increased by 3.5 times with 1-day increase in the ICU. Conclusion: Our study concluded that the patients with newly detected diabetes and stress hyperglycemia had more severe illness as compared to the known diabetics.","PeriodicalId":294186,"journal":{"name":"Journal of Diabetes and Endocrine Practice","volume":"25 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"120955648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The gulf association of endocrinology and diabetes is born: History in the making","authors":"Nasreen Alsayed, Yousef Saleh, N. Aljuhani","doi":"10.4103/jdep.jdep_9_21","DOIUrl":"https://doi.org/10.4103/jdep.jdep_9_21","url":null,"abstract":"","PeriodicalId":294186,"journal":{"name":"Journal of Diabetes and Endocrine Practice","volume":"181 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121202871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
W. Hussein, T. Elhadd, B. Afandi, Khaled Al Dahmani, N. Al Johani, N. Aljuhani, Ali Al Mamari, A. Alzahrani, Yousef Saleh, Nasreen Alsayed
{"title":"The Free Communications of the Eighth Clinical Congress (Virtual) of the Gulf Chapter of the American Association of Clinical Endocrinologists; November 5–7, 2020","authors":"W. Hussein, T. Elhadd, B. Afandi, Khaled Al Dahmani, N. Al Johani, N. Aljuhani, Ali Al Mamari, A. Alzahrani, Yousef Saleh, Nasreen Alsayed","doi":"10.4103/jdep.jdep_19_20","DOIUrl":"https://doi.org/10.4103/jdep.jdep_19_20","url":null,"abstract":"","PeriodicalId":294186,"journal":{"name":"Journal of Diabetes and Endocrine Practice","volume":"51 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130463804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A dedicated issue for a special congress!","authors":"S. Beshyah","doi":"10.4103/jdep.jdep_5_21","DOIUrl":"https://doi.org/10.4103/jdep.jdep_5_21","url":null,"abstract":"","PeriodicalId":294186,"journal":{"name":"Journal of Diabetes and Endocrine Practice","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132981467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Honnegowda, P. Shetty, H. Shashikiran, N. Nandeesh, P. Arun, Joysna Thayyil
Background: Preclinical and clinical studies have shown the importance of calorie restriction diet in weight reduction and cardiovascular risk factors. In this study, our objective is to compare the naturopathic-based short-term fasting therapy with low-calorie diet (LCD) on anthropometric and lipid profile among obese and overweight persons. A total number of subjects (n = 100) with body mass index (BMI) ≥25 were randomly allocated into either fasting therapy intervention (n = 48) or a LCD (n = 52). Materials and Methods: Participants underwent very LCD (288–904 kcal) in fasting therapy and a LCD (1234 kcal) in the other group respectively for 10 days. Individuals in both the groups were assessed with anthropometric parameters such as BMI, weight, waist circumference, hip circumference and waist-hip ratio, serum lipid profile, and serum leptin levels at the baseline and after 10 days. Results: The anthropometric measurements were decreased significantly in the fasting group when compared with the LCD group (P < 0.05). The decrease in mean serum total cholesterol (TC) (−27.43%), triglycerides (TGs) (−13.05%), and low-density lipoprotein (LDL) (−20.9%) in the treated group were statistically significant (P < 0.001), whereas serum high density lipoprotein (2.32%) was increased but insignificantly (P > 0.001) when compared with the nontreated group. Conclusions: Our findings support that short-term fasting therapy is beneficial in anthropometric measures and reducing leptin level among obese or overweight person compared to LCD. However, long-term adherence of weight loss with these interventions should be tested in future studies with bigger sample size.
{"title":"Effect of Fasting Therapy and Low-Calorie Diet on Anthropometric and Serum Lipids in Obese Females","authors":"T. Honnegowda, P. Shetty, H. Shashikiran, N. Nandeesh, P. Arun, Joysna Thayyil","doi":"10.4103/jdep.jdep_10_19","DOIUrl":"https://doi.org/10.4103/jdep.jdep_10_19","url":null,"abstract":"Background: Preclinical and clinical studies have shown the importance of calorie restriction diet in weight reduction and cardiovascular risk factors. In this study, our objective is to compare the naturopathic-based short-term fasting therapy with low-calorie diet (LCD) on anthropometric and lipid profile among obese and overweight persons. A total number of subjects (n = 100) with body mass index (BMI) ≥25 were randomly allocated into either fasting therapy intervention (n = 48) or a LCD (n = 52). Materials and Methods: Participants underwent very LCD (288–904 kcal) in fasting therapy and a LCD (1234 kcal) in the other group respectively for 10 days. Individuals in both the groups were assessed with anthropometric parameters such as BMI, weight, waist circumference, hip circumference and waist-hip ratio, serum lipid profile, and serum leptin levels at the baseline and after 10 days. Results: The anthropometric measurements were decreased significantly in the fasting group when compared with the LCD group (P < 0.05). The decrease in mean serum total cholesterol (TC) (−27.43%), triglycerides (TGs) (−13.05%), and low-density lipoprotein (LDL) (−20.9%) in the treated group were statistically significant (P < 0.001), whereas serum high density lipoprotein (2.32%) was increased but insignificantly (P > 0.001) when compared with the nontreated group. Conclusions: Our findings support that short-term fasting therapy is beneficial in anthropometric measures and reducing leptin level among obese or overweight person compared to LCD. However, long-term adherence of weight loss with these interventions should be tested in future studies with bigger sample size.","PeriodicalId":294186,"journal":{"name":"Journal of Diabetes and Endocrine Practice","volume":"64 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133331748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Surendra P. Verma, V. Singhal, H. Gupta, Imran Khan, K. Anil Kumar, N. Dara
Background and Objectives: Thyroid disorders are very common in the general population, and it is second only to diabetes as the most common condition to affect the endocrine system. In this study, we try to observe the prevalence of the type of thyroid dysfunction in patients with type 2 diabetes mellitus (T2DM). and its effect on glycemic parameters and the prevalence of autoimmune thyroid disorder in patients with T2DM. Settings and Design: This study included adults having T2DM. Patients were explained about the nature of the study and consent was obtained. Materials and Methods: Clearance was taken from the ethics committee. All participants who met the inclusion criteria were subjected to detailed clinical examination and relevant investigation. Statistical Analysis: Chi-square test was used for the analysis. Results: Two hundred and thirty-four patients (112 males and 122 females) were included in the study. The mean body mass index was high (26.21 ± 3.13 kg/m2). The mean hemoglobin (Hb) A1c was 8.81% ± 1.96%, whereas mean HbA1c in patients with both T2DM and thyroid dysfunction was 9.68% ± 1.35%. Thyroid dysfunction was found in 84 cases (35.8%), out of which the most common thyroid abnormality was overt hypothyroidism (61.9%) followed by subclinical hypothyroidism (27.3%). Out of 84 cases with thyroid dysfunction anti-thyroid peroxidase (TPO) was found positive in 45 cases (53.5%), and the most common thyroid dysfunction associated with positive anti-TPO was subclinical hypothyroidism (44%). Conclusions: The study shows a high prevalence of thyroid dysfunction among patients with T2DM and its association with poor glycemic control. The study also shows the prevalence of anti-TPO among patients and its significant correlation with thyroid dysfunction.
{"title":"Prevalence of Thyroid Disorders in Patients with Type 2 Diabetes Mellitus","authors":"Surendra P. Verma, V. Singhal, H. Gupta, Imran Khan, K. Anil Kumar, N. Dara","doi":"10.4103/jdep.jdep_12_19","DOIUrl":"https://doi.org/10.4103/jdep.jdep_12_19","url":null,"abstract":"Background and Objectives: Thyroid disorders are very common in the general population, and it is second only to diabetes as the most common condition to affect the endocrine system. In this study, we try to observe the prevalence of the type of thyroid dysfunction in patients with type 2 diabetes mellitus (T2DM). and its effect on glycemic parameters and the prevalence of autoimmune thyroid disorder in patients with T2DM. Settings and Design: This study included adults having T2DM. Patients were explained about the nature of the study and consent was obtained. Materials and Methods: Clearance was taken from the ethics committee. All participants who met the inclusion criteria were subjected to detailed clinical examination and relevant investigation. Statistical Analysis: Chi-square test was used for the analysis. Results: Two hundred and thirty-four patients (112 males and 122 females) were included in the study. The mean body mass index was high (26.21 ± 3.13 kg/m2). The mean hemoglobin (Hb) A1c was 8.81% ± 1.96%, whereas mean HbA1c in patients with both T2DM and thyroid dysfunction was 9.68% ± 1.35%. Thyroid dysfunction was found in 84 cases (35.8%), out of which the most common thyroid abnormality was overt hypothyroidism (61.9%) followed by subclinical hypothyroidism (27.3%). Out of 84 cases with thyroid dysfunction anti-thyroid peroxidase (TPO) was found positive in 45 cases (53.5%), and the most common thyroid dysfunction associated with positive anti-TPO was subclinical hypothyroidism (44%). Conclusions: The study shows a high prevalence of thyroid dysfunction among patients with T2DM and its association with poor glycemic control. The study also shows the prevalence of anti-TPO among patients and its significant correlation with thyroid dysfunction.","PeriodicalId":294186,"journal":{"name":"Journal of Diabetes and Endocrine Practice","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129932435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background and Objective: Chronic hepatitis C infection can affect glycemic control in patients with diabetes mellitus (DM). This study was done to assess the influence of hepatitis C viral infection compared to hepatitis B viral infection and noninfected cases on the occurrence of secondary oral anti-hyperglycemic drugs (OADs) failure in type 2 diabetes mellitus (T2DM) patients. Patients and Methods: This prospective study was conducted on 1293 T2DM patients who had their hepatitis B and C status checked by the enzyme-linked immunosorbent assay method. Glycemic management was done according to the standard guidelines, and glycemic control was reviewed after 6 months of enrollment. Patients who had hemoglobin HbA1c >7.5% in spite of taking >75% of the maximum dosage of three OADs, that is, metformin, sulfonylurea, and thiazolidinediones were selected. Those who were already taking insulin therapy regardless of HbA1c were also considered as secondary OADs failure. The status of secondary OADs failure was analyzed in three groups: hepatitis C virus (HCV) positive, hepatitis B virus (HBV) positive, or noninfected patients. Results: Of selected 1293 cohorts, DM with HCV positive was 152 (11.7%), and DM with HBV positive was 111 (8.5%). Among 152 HCV-positive patients, secondary OADs failure was detected in 64 (42.1%), and in those with 111 HBV-positive patients, it was detected in 30 patients (27.02%), whereas it was 177 of 1030 noninfected patients (17.1%). Conclusion: Hepatitis C infection is more common than hepatitis B infection among diabetes patients. Secondary OADs failure is significantly associated with HCV-infected diabetes patients compared to other groups, and timely consideration of insulin initiation is important in these cases.
{"title":"Secondary Oral Anti-hyperglycemic Drugs Failure in Type 2 Diabetes Patients Infected with Hepatitis C Virus","authors":"T. Aye, Htar Aye, ei-Sandar Oo","doi":"10.4103/jdep.jdep_6_19","DOIUrl":"https://doi.org/10.4103/jdep.jdep_6_19","url":null,"abstract":"Background and Objective: Chronic hepatitis C infection can affect glycemic control in patients with diabetes mellitus (DM). This study was done to assess the influence of hepatitis C viral infection compared to hepatitis B viral infection and noninfected cases on the occurrence of secondary oral anti-hyperglycemic drugs (OADs) failure in type 2 diabetes mellitus (T2DM) patients. Patients and Methods: This prospective study was conducted on 1293 T2DM patients who had their hepatitis B and C status checked by the enzyme-linked immunosorbent assay method. Glycemic management was done according to the standard guidelines, and glycemic control was reviewed after 6 months of enrollment. Patients who had hemoglobin HbA1c >7.5% in spite of taking >75% of the maximum dosage of three OADs, that is, metformin, sulfonylurea, and thiazolidinediones were selected. Those who were already taking insulin therapy regardless of HbA1c were also considered as secondary OADs failure. The status of secondary OADs failure was analyzed in three groups: hepatitis C virus (HCV) positive, hepatitis B virus (HBV) positive, or noninfected patients. Results: Of selected 1293 cohorts, DM with HCV positive was 152 (11.7%), and DM with HBV positive was 111 (8.5%). Among 152 HCV-positive patients, secondary OADs failure was detected in 64 (42.1%), and in those with 111 HBV-positive patients, it was detected in 30 patients (27.02%), whereas it was 177 of 1030 noninfected patients (17.1%). Conclusion: Hepatitis C infection is more common than hepatitis B infection among diabetes patients. Secondary OADs failure is significantly associated with HCV-infected diabetes patients compared to other groups, and timely consideration of insulin initiation is important in these cases.","PeriodicalId":294186,"journal":{"name":"Journal of Diabetes and Endocrine Practice","volume":"3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130354634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Haleemath Afrah, R. Sridhar, Sushith Sushith, Prathima Balakrishna, M. Hanumanthappa, Mukund P. Srinivasan, M. Ramarajan
Context: Diabetic foot ulcer (DFU) is one of the most dreaded complication of diabetes which often affects the morbidity and mortality of a diabetic. Biomarkers are required for follow-up of these patients to prevent further complications to the affected limb. Aim: The aim of this study is to evaluate ischemia-modified albumin (IMA), fibrinogen in relation with high sensitive-C-reactive protein (hs-CRP) in patients with DFUs. Methods: a hospital-based cross-sectional study was carried out among 30 patients with DFU admitted in the surgery department of tertiary care teaching hospital. The duration of the study was 2 months. Serum IMA, hs-CRP, and plasma fibrinogen levels were measured. Results: The present study has demonstrated that IMA levels (P < 0.05) and fibrinogen levels (P < 0.05) are statistically significantly elevated in patients with DFU and had significant correlation with albumin and hs-CRP (P < 0.05). Conclusions: The use of IMA, hs-CRP, and fibrinogen may be incorporated during the follow-up of type 2 diabetes mellitus patients and may probably prevent the development of DFU and also possibly prevent lower limb amputation. Further studies with a larger number of patients with DFU are necessary to reach a definitive judgment.
{"title":"Evaluation of Ischemia-Modified Albumin and Fibrinogen in Relation with High-Sensitive C-reactive Protein in Diabetic Foot Ulcers","authors":"Haleemath Afrah, R. Sridhar, Sushith Sushith, Prathima Balakrishna, M. Hanumanthappa, Mukund P. Srinivasan, M. Ramarajan","doi":"10.4103/jdep.jdep_15_19","DOIUrl":"https://doi.org/10.4103/jdep.jdep_15_19","url":null,"abstract":"Context: Diabetic foot ulcer (DFU) is one of the most dreaded complication of diabetes which often affects the morbidity and mortality of a diabetic. Biomarkers are required for follow-up of these patients to prevent further complications to the affected limb. Aim: The aim of this study is to evaluate ischemia-modified albumin (IMA), fibrinogen in relation with high sensitive-C-reactive protein (hs-CRP) in patients with DFUs. Methods: a hospital-based cross-sectional study was carried out among 30 patients with DFU admitted in the surgery department of tertiary care teaching hospital. The duration of the study was 2 months. Serum IMA, hs-CRP, and plasma fibrinogen levels were measured. Results: The present study has demonstrated that IMA levels (P < 0.05) and fibrinogen levels (P < 0.05) are statistically significantly elevated in patients with DFU and had significant correlation with albumin and hs-CRP (P < 0.05). Conclusions: The use of IMA, hs-CRP, and fibrinogen may be incorporated during the follow-up of type 2 diabetes mellitus patients and may probably prevent the development of DFU and also possibly prevent lower limb amputation. Further studies with a larger number of patients with DFU are necessary to reach a definitive judgment.","PeriodicalId":294186,"journal":{"name":"Journal of Diabetes and Endocrine Practice","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114748336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：